Foveal geographic atrophy following intravitreal pegaptanib sodium (Macugen) for drusenoid pigment epithelium detachment

European Journal of Ophthalmology

Volumn 19, Issue 5, 2009, Pages 890-893

  Querques, Giuseppe ^a   Bux, Anna V ^a   Delle Noci, Nicola ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Age related macular degeneration; Drusenoid pigment epithelium detachment; Foveal geographic atrophy; Macugen; Pegaptanib sodium; Vascular endothelium growth factor

Indexed keywords

PEGAPTANIB;

AGED; ARTICLE; BIOMICROSCOPY; CASE REPORT; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOVEAL GEOGRAPHIC ATROPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA DISEASE; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY;

AGED; APTAMERS, NUCLEOTIDE; ATROPHY; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INJECTIONS; MACULAR DEGENERATION; RETINAL DETACHMENT; RETINAL DISEASES; RETINAL DRUSEN; RETINAL PIGMENT EPITHELIUM; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VISUAL FIELD TESTS; VITREOUS BODY;

EID: 70549091029     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900535     Document Type: Article

References (8)

1. Bressler NM, Bressier SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32: 375-413.
2. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-reiated macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39: 367-74.
3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, Inhibition VEGF Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
4. Klein ML, Ferris FL III, Armstrong J, et al, AREDS Research Group. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 2008; 115: 1026-31.
5. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 2006; 47: 3135-42.
6. Yasuhara T, Shingo T, Kobayashi K, et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci 2004; 19: 1494-504.
7. Nishijima K, Ng Y-S, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171: 53-67.
8. Grunwald JE, Metelitsina TI, Dupont JC, Ying GS, Maguire MG. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46: 1033-8.